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Abstract
Infections due to carbapenem-resistant Klebsiella pneumoniae (CR-KP) have emerged as a public health problem worldwide given their
spread dynamics and the limited therapeutic options. Our aim was to study the clinical outcome of patients with CR-KP infections in
relation to antimicrobial treatment. CR-KP infections that occurred in a 10-month period (September 2009 to June 2010) in patients
admitted to 19 intensive care units all over Greece were studied. A total of 127 CR-KP infections were reported. Central venous catheter
bacteraemia was the most frequent infection, followed by ventilator-associated pneumonia (39 (30.7%) and 35 (27.6%) cases, respectively).
Resistance to colistin, tigecycline, gentamicin and amikacin was detected in 20%, 33%, 21% and 64% of isolates, respectively. Regarding
treatment, 107 cases received active treatment, including 1 or ≥2 active antibiotics in 65 (60.7%) and 42 (39.3%) cases, respectively. The
most frequent combination was colistin plus aminoglycoside and tigecycline plus aminoglycoside (17 and 11 cases, respectively). Forty-eight
(45.2%) of the cases that received active treatment were considered clinical failures, with 23.5% mortality at 14 days. Logistic regression
analysis revealed that age ≤55 years, non-immunocompromised patients and patients who received colistin had higher successful response
rates, while patients ≤55 years old had lower mortality rates at 14 days after the introduction of active treatment. CR-KP infections are
associated with a signiﬁcant clinical failure rate. Colistin remains a valuable antimicrobial agent for treating these infections, while the rise of
resistance to the last available antibiotics further limits treatment options.
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Introduction
Carbapenem-resistant Klebsiella pneumoniae (CR-KP) is an
emerging threat both for the patient and the healthcare system
globally. Infections due to CR-KP strains usually concern
critically ill patients and are associated with high morbidity,
mortality, prolongation of hospitalization and costs [1–5].
Treatment options are limited and include aminoglycosides,
colistin, tigecycline and fosfomycin [6,7]. However, the activity
of the latter agents against CR-KP seems to also depend on pk/
pd parameters, which are still under evaluation [8–10].
Additionally, the increasing use of these antibiotics has been
followed by reports describing the emergence of Gram-neg-
ative isolates resistant to these agents [11–13].
In Greece at the beginning of the past decade VIM-1-pro-
ducing K. pneumoniae became endemic in intensive care units
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(ICUs) [14]. Subsequently, the emergence in 2007 and the
monoclonal spread of KPC-producing K. pneumoniae strains
displaced VIM-producing strains and dominated across the
country during the last 2 years [2,15]. Infections due to these
multidrug-resistant pathogens are a new reality and their
treatment constitutes a challenge, given that experience in
treating infections caused by KPC-producing isolates is limited
and the optimal treatment either as monotherapy or as
combination therapy has not yet been established. The aim of
this study was to investigate the characteristics of patients with
infections due to CR-KP pathogens, as well as their outcome in
relation to antimicrobial treatment.
Material and Methods
In December 2009 the Hellenic Center for Disease Control
and Prevention invited all (69) ICUs in the country to
participate in this multicentre study. Of them, 19 ICUs agreed
to participate. These were ICUs providing services to both
medical and surgical patients and had a mean number of eight
beds (range, 5–12 beds).
From September 2009 through to June 2010, all ICU
patients with a microbiologically conﬁrmed infection due to
CR-KP were recorded. Data were collected retrospectively
during September–December 2009 and prospectively during
January–June 2010. The following data were collected using
one form per case: demographic, underlying and epidemio-
logic characteristics, microbiological data and clinical
response to therapeutic schemes. Data were collected by
one trained physician per ICU. The forms were sent to the
Hellenic Center for Disease Control and Prevention for
statistical analysis. The study has been performed in accor-
dance with the 1964 Declaration of Helsinki and its later
amendments.
Bloodstream infection, ventilator-associated pneumonia
(VAP), urinary tract infection, intra-abdominal infection and
surgical site infection were deﬁned in accordance with the
CDC/NHSN deﬁnitions [16]. APACHE II score was deter-
mined as follows: low severity (0–14 score), medium severity
(15–19 score) and high severity (≥20 score). Active antimi-
crobial treatment was deﬁned as antimicrobial therapy with
≥1 active agent according to the susceptibility test adminis-
tered for ≥48 h. Active monotherapy was deﬁned as therapy
with one active agent according to the susceptibility test,
whereas active combined treatment was deﬁned as a
combination with >1 active agent according to the suscep-
tibility test. We determined the clinical outcome at 14 days
after the introduction of active antimicrobial treatment for
the CR-KP infection (successful response or failure) and the
ICU mortality as the ﬁnal outcome during ICU hospitalization
(discharge or death). Successful response was deﬁned as the
absence or improvement of clinical signs and/or symptoms of
the patient at 14 days after the introduction of active
antimicrobials. Failure was deﬁned as the worsening or
persistence of clinical signs and/or symptoms, the relapse of
infection, and/or the death of the patient at 14 days after the
introduction of active treatment. Colistin was given every 8–
12 h for a total daily dose of 9 9 106 IU. The loading dose
was used with tigecycline, which was administered every 12 h
(100–200 mg/day). Gentamicin was administered every 24 h
(total daily dose 4–5 mg/kg) and meropenem was adminis-
tered by extended infusion at a dose of 2 g every 8 h. Drug
dosages were adjusted on the basis of creatinine clearance.
The clinical samples collected from the patients were
tested for CR-KP using the following methods. (i) Identiﬁ-
cation and routine susceptibility testing was performed using
various automated systems, mainly the Vitek-2 system
(Biomerieux, Marcy l Etoile, France). Tigecycline MIC was
determined using E-test methodology. Antimicrobial agent
MICs were evaluated according to the Clinical and Labora-
tory Standards Institute guidelines (CLSI) [17] whereas
colistin and tigecycline MICs were interpreted in accordance
with European Committee on Antimicrobial Susceptibility
Testing breakpoints (EUCAST) [18]. (ii) In most cases,
boronic acid and EDTA test methodologies were used for
detecting isolates producing KPC or MBL carbapenemases,
respectively [19,20].
Statistical analysis
The chi-square test was applied to test the association
between categorical variables. Multiple logistic regression
(forward likelihood ratio election) was applied, with entry
criterion based on the signiﬁcance of the score statistic and
removal criterion based on the probability of a likelihood
ratio statistic deﬁned by the partial likelihood estimates, in
order to investigate the association between the outcome
and the characteristics of the patients. Multiple logistic
regression was also applied in order to investigate the
association of VAP or central venous catheter (CVC)-related
bacteraemia with the characteristics of patients. p-Values of
≤0.05 were considered statistically signiﬁcant. Statistical
analysis was performed using the SPSS software (v.13; SPSS
Inc., Chicago, IL, USA).
Results
Nineteen ICUs reported 127 CR-KP microbiologically docu-
mented infections. Data were collected retrospectively in
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52.8% of cases and prospectively in 47.2% of cases. Α
comparison of the two subgroups did not reveal any signiﬁcant
differences. Patients had a mean age of 61.3 years (range, 17–
86 years), severe co-morbidities and a mean Apache II Score
at admission of 18.2 (range, 0–40). Most patients had
prolonged hospitalization before CR-KP isolation (mean
overall and ICU hospitalization 27.3 and 22.2 days, respec-
tively), 120 (94.5%) were intubated (mean intubation 24 days)
and 71 (55.9%) had a central venous catheter (mean
catheterization 9.2 days). Overall, patients had received a
mean of 2.3 different antibiotics, in terms of prior antimicrobial
treatment for another septic episode, in the past 10 days
before the onset of CR-KP infection (Table 1).
CVC-related bacteraemia was the most frequent CR-KP
infection, followed by VAP and primary bacteraemia (Table 2).
Twenty-two per cent of the infections were polymicrobial and
half of them concerned VAP cases. A comparison of the 35
VAP cases with the 39 CVC-related bacteraemia cases
revealed that the former were more frequently polymicrobial
(41.2% vs. 17.9%; p-value 0.039); no other statistically signif-
icant difference was found between them in terms of patient
characteristics. The most common co-pathogen for K. pneu-
moniae was Αcinetobacter baumannii (51.7%), followed by
Pseudomonas aeruginosa (37.9%). All co-pathogens were sus-
ceptible to antimicrobials administrated for treating CR-KP
infections.
Resistance to ciproﬂoxacin, aztreonam, piperacilin/tazobac-
tam, colistin, tigecycline, gentamicin and amikacin was detected
in 99%, 99%, 99%, 20%, 33%, 21% and 64% of tested CP-KP
isolates, respectively. The mechanism of carbapenem resis-
tance was investigated in 82 isolates and revealed a KPC-pro-
ducing pathogen in 52 (56.5%) cases, a VIM-producing
pathogen in 22 (23.9%) cases, and a pathogen expressing both
KPC and VIM carbapenemases in six (6.5%) cases. The MIC50
and MIC90 and the range of MICs of pathogens to meropenem,
gentamycin, colistin and tigecycline are shown in Table 3.
In terms of treatment for the speciﬁc CR-KP infection,
active antimicrobial treatment was administered to 107 cases,
while 20 cases received inappropriate treatment (mean
duration of antibiotic treatment, 8.7 days; range, 2–22 days).
The overall failure rate at 14 days was 47.2%, whereas the
mortality at 14 days and the ICU mortality were 25.2% and
51.3%, respectively. Five patients died before the fourth day of
antimicrobial treatment due to the septic episode. Table 4
shows the administered active antibiotics and the associated
clinical outcome. Among the 107 cases, 65 (60.7%) received
one active antibiotic and 42 (39.3%) received ≥2 active
antibiotics; at least one active drug was introduced within
3 days after the onset of infection in 76.5% of cases. A
carbapenem was administered in combination in 20 cases, and
only in one of them was considered to be microbiologically
active (19 isolates with MIC >16 mg/dL and one KPC-pro-
ducing isolate with MIC = 2 mg/dL).
Among the 107 cases who received active treatment, 48
(45.2%) were considered failures, including 25 who succumbed
within 14 days after the introduction of treatment (23.5%
mortality in 14 days). Among patients who received active
treatment, tigecycline-treated patients (monotherapy or com-
bination therapy with tigecycline) had the highest failure and
mortality rates. Patients having active combination therapy had
a higher successful outcome compared with those who
received active monotherapy or inappropriate therapy (Fig. 1).
Among seven cases who received inappropriate therapy, four
concerned CVC-related bacteraemias and clinical improve-
TABLE 1. Patients’ characteristics
Characteristic N (%)a
Male gender 86 (68.3)
Underlying conditions
Diabetes mellitus 31 (24.4)
Chronic obstructive pulmonary disease 29 (22.8)
Chronic renal failure 17 (13.4)
Chronic heart failure 24 (18.9)
Chronic hepatic failure 4 (3.1)
Obesity 19 (15)
Immunosuppressionb 14 (11.0)
APACHE score II
Low severity 36 (32.1)
Medium severity 18 (16.1)
High severity 58 (51.8)
Prior use of antibioticsc
Carbapenems 49 (38.6)
Colistin 32 (25.2)
Tigecycline 20 (15.7)
Aminoglycosides 24 (18.9)
Quinolones 29 (22.8)
Beta-lactam inhibitors 45 (35.4)
aAbsolute numbers do not always add up to 127 total cases because of missing
data.
bThe cause of immunosuppression was deﬁned in ten patients: splenectomy (four
patients), malignancy (three patients), and chronic renal failure, prolonged steroid
use and multiple sclerosis (one patient each).
cAntibiotic use in the past 10 days before the onset of CR-KP infection.
TABLE 2. Type of infections due to CR-KP pathogens
Type of infection
N (%)
(n = 127
Ventilator-associated pneumonia 35 (27.6)
Central venous catheter bacteraemia 39 (30.7)
Primary bacteraemia 30 (23.6)
Urinary tract infection 13 (10.2)
Surgical site infection 4 (3.1)
Intra-abdominal infection 6 (4.7)
TABLE 3. Antimicrobial susceptibility of pathogens
Antimicrobials
MIC (lg/mL)
MIC50 MIC90 MICs range
Meropenem ≥32 ≥32 1–≥32
Colistin 1 8 0.19–≥32
Gentamicin 2 8 ≤0.5–≥32
Tigecycline 2 ≥8 0.5–≥8
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ment was associated with the removal of the CVC. All the
patients having inappropriate treatment with a fatal outcome
succumbed before the microbiological report was available.
No statistically signiﬁcant difference was found between the 35
VAP cases and the 39 CVC-related bacteraemia cases in terms
of clinical outcome and mortality rate (data not shown).
A logistic regression analysis was conducted in order to
investigate the association between the clinical outcome and
the patient characteristics, including active treatment with
colistin, tigecycline, aminoglycosides and/or carbapenems,
administration of active monotherapy or active combination
therapy or inappropriate therapy (Fig. 1). Separate combina-
tions of antibiotics were not included in the model because of
the small number of patients in each category. The logistic
regression analysis revealed that patients ≤55 years old had
statistically signiﬁcantly higher successful response rates
compared with patients 56–65 years old, 66–75 years old
and >75 years old (76.5% vs. 56.7%, 40% and 30.8%, respec-
tively; p-value <0.001), and that non-immunocompromised
patients had statistically signiﬁcantly higher successful response
rates compared with immunocompromised patients (55.4% vs.
23.1%, respectively; p-value 0.015). Regarding the clinical
outcome at 14 days in association with the administrated
antibiotic, the use of colistin was associated with higher clinical
response rates compared with the use of an antimicrobial
regimen without colistin (62.5% vs. 43.5%; p-value 0.013). In
addition, mortality at 14 days was statistically signiﬁcantly
associated with patient age (8.8%, 26.7%, 22.2% and 48.1% for
patients ≤55 years old, 56–65 years old, 66–75 years old and
>75 years old, respectively; p-value 0.002). Logistic regression
analysis revealed that patients with high APACHE II scores
were more likely to receive tigecycline compared with patients
with medium and low APACHE II scores (41.4% vs. 33.3% and
13.9%, respectively; p-value 0.023), while patients with VAP
were less likely to receive treatment including an aminoglyco-
side (28.6% vs. 47.8%; p-value 0.046). A logistic regression
analysis comparing the VAP cases with CVC-related bacter-
aemia cases revealed that the former received signiﬁcantly less
frequently an aminoglycoside (28.6% vs. 51.3%; p-value 0.025).
No other statistically signiﬁcant difference was found.
Discussion
This is one of the largest series of CR-KP infections in patients
admitted to ICUs; approximately half of the cases were studied
prospectively. The large number of cases gave us the
opportunity to evaluate their outcome in relation to the
administered antimicrobial treatment. In accordance with
other studies in critically ill patients [21,22], clinical failure
rate, mortality rate at 14 days and ICU mortality rate were
signiﬁcantly high. As other researchers have already shown
[21–24], older age and immunodeﬁciency were also associated
independently with a poor clinical response.
TABLE 4. Clinical outcome at 14 days, ICU mortality and
administered antimicrobial treatment (n = 127)
Antimicrobial agents No
Failure at
14 days (%)
Mortality at
14 days (%)
ICU
mortality
(%)
Colistin monotherapy 26 32.0 23.1 45.8
Aminoglycoside
monotherapy
22 45.5 22.7 52.4
Tigecycline
monotherapy
16 68.8 31.3 66.6
Tigecycline plus
aminoglycoside
11 45.5 18.1 44.4
Colistin plus
aminoglycoside
17 35.2 11.7 40.0
Colistin plus tigecycline 9 55.5 44.4 55.5
Colistin plus tigecycline
plus aminoglycoside
4 50.0 0.0 25.0
Colistin plus tigecycline
plus carbapenem
1 — — —
Quinolones 1 — — —
Inappropriate therapy 20 63.2 35.0 58.8
FIG. 1. Outcome of patients by administered antimicrobial treatment (n = 127 cases). *Twenty infections were treated with a combination
regimen including carbapenems. Only in one case was the pathogen MIC <4 lg/dL.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O117–O123
O120 Clinical Microbiology and Infection, Volume 20 Number 2, February 2014 CMI
In our study, active therapy with colistin had a superior
clinical response at 14 days compared with other active
treatments. Our results do not differ from others in terms of
outcome at 14 days [3,5,21] and ICU mortality [24,25]. In our
study the unexpected ﬁnding was the superiority of colistin
monotherapy in relation to failure at 14 days compared with
combination regimens of the drug. For infections due to
carbapenem-resistant pathogens, especially due to Acinetobac-
ter sp., the efﬁcacy of colistin monotherapy has not been found
to be inferior compared with combination treatment [26,27].
However, two recent reviews on CR-KP infections indicate
failure rates of colistin monotherapy as high as 50–86%, which
were signiﬁcantly decreased when colistin was combined with
another active agent, especially with a carbapenem [7,28].
Additionally, in two series with similar numbers of colis-
tin-treated patients to ours [22,25], mortality rates of patients
receiving colistin monotherapy ranged from 45% to 51%,
whereas mortality of patients in colistin combination therapy
ranged from 12.5% in carbapenem-including combination
regimens to 30% and 50% in combinations with active
antimicrobials other than a carbapenem. In our study, MICs
to carbapenems were ≥32 lg/mL, whereas synergistic results
have been recorded in vivo in association with MICs ≤4 lg/mL
[1,24,25].
Our results revealed a high failure rate among tigecy-
cline-treated patients, especially among those who received
the drug as monotherapy. The clinical cure rates of tigecy-
cline-treated patients range largely in the literature. In a series
of 45 patients with infections due to carbapenem-resistant
A. baumanii or K. pneumoniae, the clinical success rate was 90%
and MICs of K. pneumoniae isolates to tigecycline were very
low, which is attributed to the limited use of the drug in their
setting [29]. In another study including 60 bloodstream
infections due to CR-KPs strains, a high mortality rate at
14 days was observed regardless of the administration of
tigecycline or another agent [30]. In this latter study, 98% of
tested isolates were susceptible to tigecycline. In our study,
67% of CR-KP clinical isolates were susceptible to tigecycline,
23% of tigecycline-treated patients had already received
treatment with the drug before the onset of the CR-KP
infection and there was a statistically signiﬁcant association
between treatment with tigecycline and high APACHE score II.
In addition, 75% of the susceptible to tigecycline CR-KP clinical
isolates for which the MICs were reported, had a MIC to
tigecycline of 2 lg/mL, which is the cut-off MIC according to
EUCAST breakpoints. These borderline MICs in association
with the low serum concentration of the drug [31] could
contribute to treatment failure in our cohort. This is in
accordance with reports [32–35] where fatal cases have been
attributed to the in vivo increase of MIC to tigecycline during
therapy. A recent analysis of 13 clinical trials found an
increased mortality risk in tigecycline-treated patients com-
pared with other drugs, warning against the use of tigecycline
in serious infections [36].
Combination treatment with more than one active agent is
preferred for serious infections caused by CR-KPs [25,28,37].
In a recent multicentre retrospective study of 125 patients
with bacteraemia due to CR-KPs [25], a combination treat-
ment of drugs with in vitro activity against the pathogen was
associated with signiﬁcantly lower mortality rates compared
with those of monotherapy treatment (34.1% vs. 54.3%); the
most successful regimen used was the combination of three
antimicrobials, colistin plus tigecyclin plus meropenem [25].
Similar results have been reported by a smaller series of
bloodstream infections due to CR-KP isolates [37]. In our study,
despite the fact that combination therapy had the lowest failure
and mortality rate compared with other treatment regimens,
the lack of carbapenems in active combined regimens and the
borderline tigecycline MICs could explain the absence of
statistically signiﬁcant superiority of combined treatment
compared with monotherapy or inappropriate therapy.
In conclusion, our multicentre ICU study showed that
infections caused by CR-KP are associated with high clinical
failure and mortality rates. Colistin remains a valuable antimi-
crobial agent whereas tigecycline might be used with caution in
serious infections. However, there are critical issues for
tigecycline and colistin regarding pk/pd evaluation that have
not been clariﬁed, in association with reports about the
emergence of colistin-resistant CR-KP strains in the frame of
extensive colistin consumption [11–13,34]. The role of carba-
penems in the treatment of CR-KP infections should be further
studied; wide-ranging MICs, even in the susceptibility area,
have been reported in KPC-producing strains [38].
In settings with high rates of antimicrobial resistance to the
above therapeutic options the choice of empirical regimen for
treating CR-KP infections should be based on previously
administered treatment and on the speciﬁc ICU epidemiology,
taking into consideration the resistance proﬁle of dominant
CR-KP clones. New effective antimicrobials for combating
infections due to these pathogens are urgently required. The
appropriate use of the remaining therapeutic options in
association with the strict implementation of infection control
measures [39] is of outmost importance in order to prevent
pan-drug-resistant infections.
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